Plasma inflammatory biomarkers for Huntington's disease patients and mouse model

Brain, Behavior, and Immunity

Volumn 44, Issue , 2015, Pages 121-127

  Chang, Kuo Hsuan ^a   Wu, Yih Ru ^a   Chen, Yi Chun ^a   Chen, Chiung Mei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Biomarker; Huntington's disease; Inflammation

Indexed keywords

AMANTADINE; BIOLOGICAL MARKER; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SEROTONIN UPTAKE INHIBITOR; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; INTERLEUKIN 18 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ROTAROD TEST; UNIFIED HUNTINGTON DISEASE RATING SCALE; AGE; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; HUNTINGTON DISEASE; INFLAMMATION; METABOLISM; MICROGLIA; MOTOR ACTIVITY;

ADULT; AGE FACTORS; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICROGLIA; MIDDLE AGED; MOTOR ACTIVITY; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84918528603     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.09.011     Document Type: Article

References (74)

1. Battaglia G., Cannella M., et al. Early defect of transforming growth factor beta1 formation in Huntington's disease. J. Cell. Mol. Med. 2011, 15:555-571.
2. Bettelli E., Carrier Y., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
3. Bjorkqvist M., Wild E.J., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
4. Bouchard J., Truong J., et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J. Neurosci. 2012, 32:18259-18268.
5. Brionne T.C., Tesseur I., et al. Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 2003, 40:1133-1145.
6. Browne S.E. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann. N. Y. Acad. Sci. 2008, 1147:358-382.
7. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 2002, 13:39-53.
8. Castellanos M., Leira R., et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40-46.
9. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 2007, 83:228-248.
10. Chang K.H., Chen Y.C., et al. Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. PLoS One 2012, 7:e46492.
11. Chen C.M., Wu Y.R., et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 2007, 359:335-340.
12. Dalrymple A., Wild E.J., et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007, 6:2833-2840.
13. Damsker J.M., Hansen A.M., et al. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 2010, 1183:211-221.
14. Dang D., Yang Y., et al. Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem. Biophys. Res. Commun. 2004, 316:937-942.
15. Deckel A.W., Cohen D., et al. Cerebral blood flow velocity decreases during cognitive stimulation in Huntington's disease. Neurology 1998, 51:1576-1583.
16. Di Prospero N.A., Fischbeck K.H. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet. 2005, 6:756-765.
17. Ellison S.M., Trabalza A., et al. Dose-dependent neuroprotection of VEGF(1)(6)(5) in Huntington's disease striatum. Mol. Ther. 2013, 21:1862-1875.
18. Franciosi S., Ryu J.K., et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012, 45:438-449.
19. Giorgini F., Muchowski P.J. Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol. 2005, 6:210.
20. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 1996, 11:136-142.
21. Gu Z., Cui J., et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 2005, 25:6401-6408.
22. Gu Z., Kaul M., et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
23. Harris G.J., Codori A.M., et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122:1667-1678.
24. Hasselbalch S.G., Oberg G., et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J. Neurol. Neurosurg. Psychiatry 1992, 55:1018-1023.
25. Hornebeck W., Lafuma C. Matrix metalloproteinase (MMP). C. R. Seances Soc. Biol. Fil. 1991, 185:127-134.
26. Hoshino K., Tsutsui H., et al. Cutting edge: generation of IL-18 receptor-deficient mice. evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 1999, 162:5041-5044.
27. Hsiao H.Y., Chen Y.C., et al. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum. Mol. Genet. 2013, 22:1826-1842.
28. Hsiao H.Y., Chern Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol. Neurobiol. 2010, 41:248-255.
29. Hsiao H.Y., Chiu F.L., et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum. Mol. Genet. 2014, 23:4328-4344.
30. Ilzecka J., Stelmasiak Z., et al. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 2002, 20:239-243.
31. Khoshnan A., Ko J., et al. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant Huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
32. Kim J.H., Lee H.W., et al. Microglia-inhibiting activity of Parkinson's disease drug amantadine. Neurobiol. Aging 2012, 33:2145-2159.
33. Krakora D., Mulcrone P., et al. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol. Ther. 2013, 21:1602-1610.
34. Kuo N.T., Benhayon D., et al. Prolonged hypoxia increases vascular endothelial growth factor mRNA and protein in adult mouse brain. J. Appl. Physiol. 1999, 86:260-264.
35. Lee H.G., Ueda M., et al. Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway?. J. Neurosci. Res. 2006, 84:1856-1861.
36. Lee S.R., Kim H.Y., et al. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem. Biophys. Res. Commun. 2009, 380:17-21.
37. Leoni V., Mariotti C., et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008, 131:2851-2859.
38. Li D.Q., Lokeshwar B.L., et al. Regulation of MMP-9 production by human corneal epithelial cells. Exp. Eye Res. 2001, 73:449-459.
39. Li J.Y., Popovic N., et al. The use of the R6 transgenic mouse models ofHuntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2:447-464.
40. Lin C.Y., Hsu Y.H., et al. Neurovascular abnormalities in humans and mice with Huntington's disease. Exp. Neurol. 2013, 250:20-30.
41. MacDonald M.E., Ambrose C.M., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
42. Maglione V., Giallonardo P., et al. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. Am. J. Med. Genet. B Neuropsychiatric Genet. 2005, 139B:101-105.
43. Mangiarini L., Sathasivam K., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
44. Miller J.P., Holcomb J., et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010, 67:199-212.
45. Moller T. Neuroinflammation in Huntington's disease. J. Neural Transm. 2010, 117:1001-1008.
46. Morton A.J., Morton D.S. Large genetic animal models of Huntington's disease. J Huntington's Dis. 2013, 2:3-19.
47. Moscovitch-Lopatin M., Weiss A., et al. Optimization of an HTRF assay for the detection of soluble mutant Huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr. 2010, 2:RRN1205.
48. Motta M., Imbesi R., et al. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol. Lett. 2007, 114:46-51.
49. Nagata E., Sawa A., et al. Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. Neuroreport 2004, 15:1325-1328.
50. Ojala J., Alafuzoff I., et al. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol. Aging 2009, 30:198-209.
51. Pavese N., Gerhard A., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
52. Pichiule P., LaManna J.C. Angiopoietin-2 and rat brain capillary remodeling during adaptation and deadaptation to prolonged mild hypoxia. J. Appl. Physiol. 2002, 93:1131-1139.
53. Rahman A., Ekman, et al. Late onset vascular dysfunction in the R6/1 model of Huntington's disease. Eur. J. Pharmacol. 2013, 698:345-353.
54. Rota E., Bellone G., et al. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 2006, 27:33-39.
55. Salo T., Lyons J.G., et al. Transforming growth factor-beta 1 up-regulates type IV collagenase expression in cultured human keratinocytes. J. Biol. Chem. 1991, 266:11436-11441.
56. Sapp E., Kegel K.B., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
57. Sawa A., Wiegand G.W., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 1999, 5:1194-1198.
58. Shin J.Y., Fang Z.H., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
59. Silvestroni A., Faull R.L., et al. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
60. Springer M.L., Chen A.S., et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 1998, 2:549-558.
61. Stack E.C., Matson W.R., et al. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. N. Y. Acad. Sci. 2008, 1147:79-92.
62. Tai Y.F., Pavese N., et al. Imaging microglial activation in Huntington's disease. Brain Res. Bull. 2007, 72:148-151.
63. Tesseur I., Wyss-Coray T. A role for TGF-beta signaling in neurodegeneration: evidence from genetically engineered models. Curr. Alzheimer Res. 2006, 3:505-513.
64. Tourjman V., Kouassi E., et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151:43-47.
65. Underwood B.R., Broadhurst D., et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129:877-886.
66. Valera A.G., Diaz-Hernandez M., et al. The ubiquitin - proteasome system in Huntington's disease. Neuroscientist 2005, 11:583-594.
67. Vawter M.P., Dillon-Carter O., et al. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 1996, 142:313-322.
68. Wang J., Tsirka S.E. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005, 128:1622-1633.
69. Warner-Schmidt J.L., Vanover K.E., et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9262-9267.
70. Weiss A., Trager U., et al. Mutant Huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 2012, 122:3731-3736.
71. Wild E., Magnusson A., et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011, 3:RRN1231.
72. Wildbaum G., Youssef S., et al. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 1998, 161:6368-6374.
73. Yatsiv I., Morganti-Kossmann M.C., et al. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J. Cereb. Blood Flow. Metab. 2002, 22:971-978.
74. Yue X., Hariri D.J., et al. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Neuroscience 2014, 258:385-400.